Trial · NCT02729896
Adverse events333
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 333
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ANAEMIA | Blood and lymphatic system disorders | Dose-Escalation FL Cohort 1.4 mg | 0 | 3 | 0 |
| other | ANAEMIA | Blood and lymphatic system disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 1 | 10 | 1 |
| other | ANAEMIA | Blood and lymphatic system disorders | Safety Run-in and Expansion DLBCL Cohort | 2 | 21 | 2 |
| other | ANAEMIA FOLATE DEFICIENCY | Blood and lymphatic system disorders | Dose-Escalation FL Cohort 1.4 mg | 0 | 3 | 0 |
| other | ANAEMIA FOLATE DEFICIENCY | Blood and lymphatic system disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 1 | 10 | 1 |
| other | ANAEMIA FOLATE DEFICIENCY | Blood and lymphatic system disorders | Safety Run-in and Expansion DLBCL Cohort | 0 | 21 | 0 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Dose-Escalation FL Cohort 1.4 mg | 0 | 3 | 0 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 2 | 10 | 5 |
| other | LEUKOPENIA | Blood and lymphatic system disorders | Safety Run-in and Expansion DLBCL Cohort | 1 | 21 | 1 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Dose-Escalation FL Cohort 1.4 mg | 1 | 3 | 1 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 4 | 10 | 7 |
| other | NEUTROPENIA | Blood and lymphatic system disorders | Safety Run-in and Expansion DLBCL Cohort | 3 | 21 | 4 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Dose-Escalation FL Cohort 1.4 mg | 0 | 3 | 0 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 4 | 10 | 5 |
| other | THROMBOCYTOPENIA | Blood and lymphatic system disorders | Safety Run-in and Expansion DLBCL Cohort | 0 | 21 | 0 |
| other | SINUS TACHYCARDIA | Cardiac disorders | Dose-Escalation FL Cohort 1.4 mg | 0 | 3 | 0 |
| other | SINUS TACHYCARDIA | Cardiac disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 1 | 10 | 1 |
| other | SINUS TACHYCARDIA | Cardiac disorders | Safety Run-in and Expansion DLBCL Cohort | 0 | 21 | 0 |
| other | AUTOIMMUNE THYROIDITIS | Endocrine disorders | Dose-Escalation FL Cohort 1.4 mg | 0 | 3 | 0 |
| other | AUTOIMMUNE THYROIDITIS | Endocrine disorders | Dose-Escalation and Expansion FL Cohort 1.8 mg | 1 | 10 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02729896/events